Demonstrating Clinical Success in CD19/CD20 Dual CAR Innovation to Enhance Clinical Impact

• Detailing the development rationale behind dual CAR design to address resistance challenges and broaden therapeutic applicability
• Showcasing positive IIT clinical trial data for JW Therapeutics’ JWCAR201
• Illustrating the potential of dual CAR-T platforms to advance treatment options across oncology and autoimmunity

Speakers:

Shawn He

Chief Scientific Officer

JW Therapeutics